The question sounds simple. The answer changes depending on who you ask, where you live, and which definition of "drug" you have in mind. Ask the DEA, and kratom is currently unscheduled at the federal level in 2026. Ask the FDA, and kratom is an unapproved substance that the agency has been warning the public about for years. Ask a pharmacologist, and kratom is a plant whose primary alkaloids bind to opioid and adrenergic receptors, which is the textbook definition of a drug acting on the body. The American Kratom Association estimates that between 11 and 16 million Americans use kratom in some form, and most of them have run into this confusion at some point.
People rarely ask "is kratom a drug" out of pure academic curiosity. They ask because their employer drug-tests, because their state passed a Kratom Consumer Protection Act, because their cousin saw a news segment about an FDA warning, or because a friend told them kratom is "basically a legal opioid" and they want to know if that is true. The "what is kratom" question and the "is kratom a drug" question are tangled together, and people often want both answered in one breath. The answer depends on the lens. Legal, pharmacological, regulatory, occupational, and cultural lenses all give different verdicts.
This guide walks through each lens with current 2026 context, including the FDA's July 2025 recommendation on concentrated 7-hydroxymitragynine products, the state-level legal patchwork, and what the science says about kratom's activity at the receptor level. We will be plainspoken about where kratom is a drug, where it is not, and where the framing is mostly semantic.
Table of Contents
- What "Drug" Really Means in 2026
- Kratom Is Pharmacologically Active
- Kratom Is Not a Federally Controlled Substance
- But the FDA Has Not Approved It Either
- State-Level Legal Status Varies
- Will Kratom Show Up on a Drug Test?
- How to Decide What "Kratom Is a Drug" Means to You
- What Responsible Use Looks Like
- Frequently Asked Questions
- Final Thoughts
TL;DR
- Kratom is pharmacologically active, so by the scientific definition of a drug, it is one. Its main alkaloids bind to mu-opioid and other receptors.
- Kratom is not federally scheduled in 2026, so by the DEA definition of a controlled drug, it is not.
- The FDA has not approved kratom as a medicine or recognized it as a dietary supplement, so by the FDA definition, it sits in regulatory limbo.
- State law varies. About six states ban kratom outright, and roughly eight have passed Kratom Consumer Protection Acts that set age limits and labeling rules.
- Standard 5-panel and 10-panel workplace drug tests do not detect kratom. Specialized kratom panels do.
- The FDA recommended scheduling concentrated 7-hydroxymitragynine products as Schedule I in July 2025. The DEA review is ongoing as of 2026.
- Calling kratom "a drug" or "not a drug" without context misses how different stakeholders use the word. Pick the lens you care about.
- If you choose to use kratom, single-strain lab-tested products and reasonable serving sizes are the responsible-use floor.
What "Drug" Really Means in 2026
The word "drug" gets used in at least four distinct senses, and conflating them is the main reason this question feels confusing. The first sense is the DEA sense, which refers to a controlled substance listed on one of the five federal schedules. The second sense is the pharmacological sense, which refers to any substance that produces a biological effect when introduced into the body. The third sense is the FDA sense, which refers to an article intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and which the FDA has reviewed and approved. The fourth sense is the lay or cultural sense, which is loose and tends to map to "something that gets you high" or "something on the no-fly list at work."
Kratom maps differently onto each of those four senses. It is a drug under the pharmacological definition. It is not a drug under the DEA scheduled-substance definition, at least at the federal level in 2026. It is not an approved drug under the FDA medicine definition. Under the cultural definition, opinions vary wildly depending on the speaker. A coworker in HR and a botanical-medicine researcher will give you different answers, and both will be technically right within their own frame.
Why the lens matters for the "is kratom a drug" question
When a state legislator says "is kratom a drug," they usually mean "should it be scheduled and restricted by law." When a researcher says it, they mean "does it act on receptors." When a job applicant says it, they mean "will this make me fail a drug test." Each question has a clean answer once you fix the lens. The kratom drug debate sounds endless mostly because participants keep switching lenses without saying so. People also tend to mix up "is kratom a drug" with the separate question of whether kratom is addictive, and we cover that distinction below.
Kratom Is Pharmacologically Active
Kratom contains more than 40 identified alkaloids, with mitragynine and 7-hydroxymitragynine being the two most studied. According to the National Institute on Drug Abuse, both alkaloids interact with mu-opioid receptors as partial agonists, which means they activate the receptor but with lower efficacy than full opioid agonists like morphine. Mitragynine also interacts with alpha-2 adrenergic receptors and serotonergic 5-HT receptors at different concentrations, which is part of why people report different effects at different serving sizes.
By the pharmacological definition, that activity profile makes kratom a drug. It produces measurable biological effects through receptor binding. Whether you find that activity helpful, neutral, or concerning is a separate question. A 2024 review in PMC's open-access library consolidated the receptor pharmacology data and noted that mitragynine's pharmacology does not perfectly mirror classical opioids, which is why kratom's effects and risk profile differ from prescription opioids in meaningful ways. Whether kratom is addictive at typical use patterns is a related but separate research question covered briefly in the FAQ below.
The alkaloid breakdown most users care about
The two alkaloids that drive most of kratom's user-reported effects are mitragynine, typically the most abundant alkaloid in dried leaf, and 7-hydroxymitragynine, present in trace amounts in fresh leaf but generated in higher quantities when leaf is oxidized or concentrated. Concentrated 7-OH products, which are not the same thing as whole-leaf kratom powder, have become the regulatory flashpoint in 2025 and 2026. The distinction matters because the FDA's July 2025 scheduling recommendation specifically targeted concentrated 7-OH formulations, not natural leaf. For context on the broader alkaloid family, our internal guide on what alkaloids are and why they matter goes deeper into the chemistry.
Kratom Is Not a Federally Controlled Substance
In 2026, kratom is not listed on any of the DEA's five controlled-substance schedules at the federal level. That is the short version of the federal kratom drug question. The longer version is that the question of federal scheduling has been visited and revisited for nearly a decade, and the status quo has held mostly because of organized public response and a 2018 recommendation from the Department of Health and Human Services that scheduling was not appropriate at the time. So on the DEA lens, the answer to "is kratom a drug" is no, with the caveat that the FDA's 7-OH recommendation may shift part of the picture.
In August 2016, the DEA announced its intent to place mitragynine and 7-hydroxymitragynine into Schedule I on an emergency basis. The announcement triggered a public-comment-period response that was unusually large, including a White House petition with over 140,000 signatures and a congressional letter signed by 51 members of Congress. The DEA withdrew the emergency-scheduling notice in October 2016 and asked the FDA to conduct a standard scientific review. The HHS later returned a recommendation against scheduling. Federal status has been unscheduled since.
DEA and FDA scheduling timeline
| Year | Event | Outcome |
|---|---|---|
| 2016 | DEA announces intent to emergency-schedule mitragynine and 7-OH | Withdrawn after public response |
| 2018 | HHS internal review recommends against scheduling | Status quo maintained |
| 2021 | WHO Expert Committee declines to recommend international scheduling | Status quo maintained |
| 2023 | FDA continues import alert program for kratom shipments | Trade-level constraint, not scheduling |
| July 2025 | FDA recommends concentrated 7-OH products as Schedule I | DEA review pending |
| March 2026 | Group of US senators urge FDA to schedule kratom | No DEA final action as of publication |
Senator Pete Ricketts and a group of senators sent a letter to the FDA in March 2026 calling on the agency to address what the senators described as a kratom scheduling loophole. The letter is published on Senator Ricketts' Senate page. The letter is political pressure rather than a regulatory action, but it gives a sense of where the federal conversation is heading.
But the FDA Has Not Approved It Either
Federal unscheduled status does not mean federal approval. The FDA has explicitly stated that kratom is not an approved drug and is not legally marketable as a dietary supplement because it has not satisfied the agency's safety review process. The FDA's public-facing kratom page lays out the agency's position clearly, including warnings about contamination risks and adverse-event reports.
This is the regulatory limbo many users find frustrating. Kratom is sold by retailers across the country, but it is not legally a supplement, not a food additive recognized as safe, and not an approved drug. It exists in a category the FDA refers to with terms like "unapproved new drug" or "adulterated supplement," depending on how a specific product is labeled. The practical effect is that quality control, labeling honesty, and contamination testing fall to the brand rather than to a regulator.
This is why third-party lab testing matters at the brand level. A well-sourced single-strain product from a brand that lab-tests for heavy metals, pathogens, and alkaloid content gives you something the FDA cannot give you in 2026, which is verified consistency. Our internal write-up on the kratom strain map covers what those single-strain labels mean in practice.
State-Level Legal Status Varies
State law is where the kratom drug question gets practically messy. Roughly six states have banned kratom outright as of 2026, while another eight or so have passed Kratom Consumer Protection Act (KCPA) frameworks that legalize sales under age-limit and labeling requirements. Several counties and cities within otherwise legal states have their own local bans. If you travel with kratom or buy across state lines, the patchwork matters.
State-level overview
| Status | Examples (verify locally before relying on this) |
|---|---|
| Banned outright | Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin |
| KCPA-style regulated | Arizona, Colorado, Georgia, Nevada, Oklahoma, Utah, Virginia, West Virginia |
| Local-county bans | San Diego County (CA), Sarasota County (FL), several Mississippi counties, parts of Tennessee |
| Unregulated | Most remaining states default to legal without specific kratom statutes |
The American Kratom Association maintains a current map and tracks pending legislation. The KCPA pattern is the consumer-protection direction the advocacy world has pushed for, since outright bans tend to create unregulated markets rather than reduce use. The residency lens is part of what people mean when they ask whether kratom is a drug. In a state that bans it, the legal answer is yes. In a KCPA state, the legal answer is no.
Will Kratom Show Up on a Drug Test?
This is the operational version of the question for anyone who is drug-tested for work, sport, probation, or insurance. The short answer is that standard workplace drug panels do not test for kratom. The longer answer is that specialized kratom panels exist, and some employers, parole systems, and athletic associations request them.
A standard 5-panel test screens for amphetamines, cocaine, opiates, PCP, and THC. A 10-panel adds barbiturates, benzodiazepines, methadone, methaqualone, and propoxyphene. Mitragynine is structurally different from classical opiates and does not cross-react on the standard opiate immunoassay reliably. Specialized panels that use liquid chromatography mass spectrometry can detect mitragynine and 7-hydroxymitragynine for roughly five to seven days after use, depending on serving size, frequency, and individual metabolism.
If you are subject to a kratom-specific panel and want a clean test, the only reliable approach is abstaining for two to three weeks before the test. There is no detox product that reliably accelerates clearance, despite what the supplement-shelf marketing implies. Your kidneys and liver process kratom on their own schedule.
How to Decide What "Kratom Is a Drug" Means to You
The cleanest way to settle the question for your own situation is to run it through four lenses in order. Each lens gives a verifiable answer.
- Pharmacological lens. Does kratom interact with receptors in your body? Yes. Mu-opioid partial agonism, adrenergic activity, and serotonergic activity are all documented. By this lens, kratom is a drug.
- Federal legal lens. Is kratom scheduled by the DEA? Not in 2026. By this lens, kratom is not a drug in the controlled-substance sense.
- State legal lens. Is kratom legal in your specific state and locality? Check your state statute and any county or city ordinances. The answer varies. In six states the legal answer is that kratom is a banned substance.
- Occupational lens. Does your employer, sport, or licensing body test for kratom-specific markers? Most do not. Some do. If it matters for your job, ask HR what panel they run.
Running through those four steps gives you a defensible position. You can say something like, "Kratom is pharmacologically active and unscheduled federally, my state has a Kratom Consumer Protection Act, and my employer's drug panel does not include kratom-specific markers." That kind of answer is more useful than a yes-or-no verdict to the question of whether kratom is a drug.
What Responsible Use Looks Like
If you have run the four-lens test and decided to use kratom, the responsibility floor is the same regardless of how you answer the drug question. Buy from a brand that publishes third-party lab results for heavy metals, pathogens, and alkaloid content. Stick with single-strain whole-leaf products instead of concentrates. Use reasonable serving sizes, typically in the 2 to 5 gram range for most users, and let your body tell you what works rather than chasing higher amounts.
The GRH kratom dosage guide walks through serving sizes and timing in more depth. The short version is that kratom's dose-response curve is not linear, and more is not better past a certain point. Most experienced users find their sweet spot at moderate serving sizes and stay there.
Single-strain Maeng Da is a common starting point because the leaf source and processing are consistent. White Maeng Da tends to lean toward focus and energy. Green Maeng Da sits in the middle of the strain spectrum. Red Maeng Da Kratom Powder leans toward relaxation. Brand-to-brand differences in farming, drying, and milling matter as much as strain label, which is why lab-tested supply chains are the practical filter when you are evaluating a kratom drug claim or marketing line.
Frequently Asked Questions
Is kratom a Schedule 1 drug in 2026?
Not federally. At the federal level, kratom is not on any DEA schedule. Some states have placed kratom on their own controlled-substance lists, which functions like a state-level Schedule I in those jurisdictions. The FDA has recommended Schedule I status for concentrated 7-hydroxymitragynine products specifically, and the DEA review is ongoing as of 2026.
Is kratom considered a drug or a supplement?
The FDA does not currently recognize kratom as a legal dietary supplement, and the FDA has not approved kratom as a drug. So formally kratom is neither, in the agency's eyes. It is sold under botanical-product framing, which is why responsibility for testing and labeling lands on the brand rather than on a federal regulator. The "is kratom a drug or supplement" framing is technically a false binary in 2026.
Is kratom addictive?
At chronic high serving sizes, kratom has a documented dependence potential, with users reporting tolerance and a withdrawal pattern that resembles a mild opioid withdrawal in some cases. The honest answer to "is kratom addictive" is that risk scales with serving size, frequency, and individual sensitivity. Moderate, occasional use carries lower dependence risk than daily high-serving use. NIDA's published reviews go deeper into the dependence research.
Does kratom show up on a standard drug test?
No. Standard 5-panel and 10-panel workplace drug tests do not detect kratom. Specialized panels that use liquid chromatography mass spectrometry can detect mitragynine for several days after use. If your employer or licensing body runs a kratom-specific panel, that is the test to ask about.
Is kratom a prescription drug?
No. Kratom is not available by prescription in the United States. It has not gone through the FDA new-drug-approval process. Anyone marketing kratom as a treatment for a specific disease is making a claim the FDA considers unauthorized.
Is kratom a recreational drug?
That depends on the user. Some users take kratom for energy, focus, or relaxation purposes that look more like coffee use or evening tea use than recreational drug use. Other users take kratom in larger amounts or with combination patterns that look more recreational. The plant itself is not inherently recreational or therapeutic. Use pattern decides.
Is kratom a psychoactive drug?
Yes, in the literal sense that kratom alkaloids cross the blood-brain barrier and produce effects on mood, energy, and pain perception. The intensity of those effects depends on serving size and individual sensitivity. Mayo Clinic's overview describes kratom as having stimulant-like effects at low servings and opioid-like effects at higher servings.
Is kratom a hard drug?
The phrase "hard drug" is informal and not used in pharmacology or regulation. Kratom has a documented dependence potential at chronic high serving sizes, but its risk profile is meaningfully lower than classical opioids. The NIDA review on kratom covers the dependence research in more detail.
Will the DEA reschedule kratom?
As of 2026, the DEA has not signaled a final scheduling decision on kratom. The FDA's July 2025 recommendation targeted concentrated 7-hydroxymitragynine products, not whole-leaf kratom. Senate pressure exists, but the regulatory process includes a public comment period before any rule becomes final. The status quo of unscheduled federal status holds at the time of writing.
Final Thoughts
"Is kratom a drug" looks like a yes-or-no question, but it is really four questions packed into one. Pharmacologically, kratom is a drug. Federally, kratom is not a controlled drug as of 2026. From the FDA's perspective, kratom is an unapproved substance in regulatory limbo. From a state-law perspective, the answer depends on your zip code. The reason the "is kratom a drug" question keeps coming back is that none of those four answers settles the others.
The honest move is to pick the lens you care about for your situation. If you are drug-tested for work, the occupational lens is the one that matters. If you live in Indiana or Wisconsin, the state-law lens matters first. If you are deciding whether to try kratom at all, the pharmacological lens and the responsible-use lens matter most, including buying from a brand that publishes third-party lab tests. We at GRH Kratom sell single-strain lab-tested products like Green Maeng Da Kratom Powder and White Maeng Da Kratom Powder because the FDA cannot give kratom buyers the verified consistency that single-source farming and third-party testing can.
If you are still uncertain about whether kratom is a drug in any sense that matters to you, the four-lens walkthrough above is the cleanest approach. Cross-check the FDA's kratom page, the NIDA research summary, and the NCCIH kratom overview. Talk to your physician if you take prescription medications, because kratom interacts with the same metabolic pathways as many common drugs.
The single most useful reframe is this. The question is not whether kratom is a drug. The question is which definition of drug you are asking about, and what answer matters for what you are trying to do. Pick the lens, then act on what the lens tells you. That works better than waiting for a one-word verdict that no agency or scientist is going to deliver in clean form anytime soon.
